Her-2Expression In191Specimens Of Early Gastric Cancer And Its Correlation With Clinicopathologic And Prognosis

Objective： The purpose of this study was to reveal Her-2expression correlation withclinicopathologic and prognosis.This will provide evidence for clinical aplication of Herceptintargeted therapy in early gastric cancer.Methods：We collected cases with stages I-III gastric cancer in our hospital,who underwentgastrectomy from January2008to January2013. After throwing out all the ones that did not meetmy requirements, there were191cases. The immunohistochemical method was used to detect theHer-2protein status in early gastric cancer.Sum up clinicopathologic data,such as age, sex, Her-2expression, tumor differentiation, nerve invasion, vascular invasion,etc.Out-patient review,telephone follow-up study ended in October2013. Overall survival time was from surgeryday to dead or last investigation. The data is divided into two groups, Her-2positive group andHer-2negative group. Application of SPSS17.0statistical software analysis of Her-2expression intwo groups data, chi-square test analysis its correlation with age, sex and clinicopathologic data.Kaplan Meier method estimate survival rate in both groups. The Log-rank test analysis differencesin survival rate.The difference between the two groups was statistically significant(P<0.05).Results：1. Of198patients with stages I-III gastric cancer,there were40Her-2positive casesand151Her-2negative cases,Her-2positive rate was20.94%.2. Her-2positive rate of aged less than or equal40,40to65,greater than or equal65were7.69%,17.76%and28.17%, respectively.Her-2expression had tendency of increasing with age, butthere is no statistics significant (P=0.107).3. Her-2positive rate of Male and female patients with gastric cancer were20.25%and32.00%, respectively,but there is no statistics significant (P=0.614).4. Her-2positive rate of different gastric cancer locations containing preventriculus, pylorus,body,antrum were16.44%,27.27%,27.59%and27.87%, respectively,but there is no statisticssignificant (P=0.528).5. Her-2positive rate of well differentiated, moderately differentiated,poorly,differentiated,undifferentiation,were25.00%,22.86%,14.86%and66.67%,respectively,but there is no statisti-cs significant (P=0.153).6. Her-2positive rate of different tumor diameter containing less than or equal2cm,2cm to5cm,greater than or equal5cm were20%,19.13%and24.24%, respectively,but there is no statistics significant (P=0.720).7. Her-2positive rate of different invasion depth of gastric cancer containing T1,T2,T3,T4were38.46%,20.00%,14.29%and19.88%,respectively, but there is no statistics significant(P=0.395).8. Her-2positive rate of stages I, stages II, stages III were15.38%,17.78%and24.30%,respectively, but there is no statistics significant (P=0.413).9. Her-2positive rate of lymph node metastasis and no lymph node metastasis were25.20%and13.24%,respectively, the difference was statistically significant (P=0.045).10. Her-2positive rate of nerve invasion and no nerve invasion were41.18%and18.97%,respectively, the difference was statistically significant(P=0.046).11. Her-2positive rate of vascular invasion and no vascular invasion were100.00%and20.11%,respectively, the difference was statistically significant(P=0.012).12. Median survival time of positive patients and negative patients were16±2.423months,38±3.795months,respectively, the difference was statistically significant.Conclusion：1. Moderate expression of Her-2expression is shown in early gastric cancer.In early gastric cancer,there was no significant relationship between the Her-2expression and thepatient’s age, gender, tumor location, degree of differentiation，tumor size，depth of tumor invasion,and TNM staging.The expression of Her-2was closely correlated to lymphnode metastasis, nerveinvasion and vascular invasion.Overall survival in Her-2positive group is higher than negativegroup.The postoperative patients with gastric cancer,who were with lymph node metastasis,vascularinvasion,Her-2positive expression,may benefit fron Trastuzumab treatment. It is necessary to carryout Trastuzumab treatment in Her-2positive expression postoperative patients with gastric cancer,inorder to improve their survival.